glp-1 and autoimmune Inflammation: How These Drugs Ease Arthritis Emerging Data Show Potential Risk

If a dose is not working for you, a prescriber can slow titration, hold at a step, or switch products

Such hotspot interference is being reported more frequently, and radiologists warn it might lead to misdiagnoses, unnecessary follow-up procedures, or delayed treatment

The U.S Food and Drug Administration drug labels for GLP-1 receptor agonists include a warning that acute pancreatitis has been observed in patients and that treatment should be discontinued promptly if acute pancreatitis is suspected

However, a limitation of the analyzed papers is that the cohorts are not homogeneous, which could partially account for the contrasting results from different papers